ASCO 2025 – Astra "looked at" patritumab but passed
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
Uncontrolled trial strategy sinks UroGen
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
Asia stymies Columvi's expansion
Starglo isn't applicable to a US population, an adcom rules.
J&J gets a smouldering endorsement
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
AbbVie gets a cMet niche
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
